Isoxazole‐Based Compounds Targeting the Taxane‐Binding Site of Tubulin
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.70031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Miroslav Peřina und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Olomouc, Czech Republic. Hauptthemen laut MEDLINE: Tubulin, Taxoids, Antineoplastic Agents, Tubulin Modulators. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors gratefully acknowledge financial support from the Palacký University Olomouc (IGA_PrF_2025_011) and from the Czech Ministry of Education, Youth and….
Abstract (Originalsprache)
Taxanes and other tubulin‐targeting medications are essential for treating advanced malignancies, especially in patients undergoing less aggressive chemotherapy. However, their clinical efficacy is often limited by significant off‐target toxicity and adverse side effects. In this study, the synthesis and characterisation of novel steroidal A‐ring‐fused isoxazoles, which were obtained through iodine‐mediated oxidative cyclization of dihydrotestosterone (DHT)‐derived α,β‐unsaturated oximes, are reported. According to mechanistic studies, the most potent compounds induced mitotic arrest and disrupted cytoskeletal integrity at low micromolar concentrations. The lead compound, 2j , notably increased the rate of tubulin polymerisation in vitro and stabilised polymerised tubulin in the cells, leading to a G2/M block of the cell cycle. Molecular docking studies indicated that 2j is bound preferably to the taxane site on tubulin, forming conserved interactions. MicroScale Thermophoresis was used to further study this binding and showed a nanomolar K D for 2j . The fact that 2j maintained its activity in docetaxel‐resistant prostate cancer cells, demonstrating its ability to circumvent resistance pathways linked to existing therapies with taxane‐like drugs, supports its clinical relevance. Therefore, our results encourage additional research and development for its potential therapeutic use in cancer treatment, particularly in resistant cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Olomouc, Czech Republic.
- Department of Molecular and Analytical Chemistry, University of Szeged, Szeged, Hungary.
- Institute of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary.
ORCID-Profile: Miroslav Peřina, Márton A Kiss, Jakub Bělíček, Veronika Vojáčková, Denisa Veselá, Renáta Minorics, István Zupko, Éva Frank, Radek Jorda
Förderung
- The authors gratefully acknowledge financial support from the Palacký University Olomouc (IGA_PrF_2025_011) and from the Czech Ministry of Education, Youth and…
Zitieren
APA
Peřina, M., Kiss, M. A., Bělíček, J., Vojáčková, V., Veselá, D., Minorics, R., Zupko, I., Frank, É., & Jorda, R. (2025). Isoxazole‐Based Compounds Targeting the Taxane‐Binding Site of Tubulin. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70031
Vancouver
Peřina M, Kiss MA, Bělíček J, Vojáčková V, Veselá D, Minorics R, et al. Isoxazole‐Based Compounds Targeting the Taxane‐Binding Site of Tubulin. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70031
BibTeX
@article{Peina2025,
author = {Peřina, Miroslav and Kiss, Márton A and Bělíček, Jakub and Vojáčková, Veronika and Veselá, Denisa and Minorics, Renáta and Zupko, István and Frank, Éva and Jorda, Radek},
title = {Isoxazole‐Based Compounds Targeting the Taxane‐Binding Site of Tubulin},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.70031}
}
EUVIMED